"The groundwork of all happiness is health." - Leigh Hunt

Electric currents delivered to the brain at home can significantly reduce symptoms of depression – latest research

as much as a The third of the people Diagnosed with depression not responding to antidepressants or therapy.

In such cases, patients could also be prescribed neuromodulation therapy, which modulates brain activity to scale back symptoms of depression. A promising type of neuromodulation therapy that researchers are investigating is transcranial directional current stimulation (tDCS).

Transcranial direct current stimulation Delivers a weak electrical current to the brain through electrodes which might be placed on the pinnacle by a band or strap. It changes the excitability of the brain tissue under the electrodes. Reducing stimulation of overactive areas and increasing stimulation of inactive areas, especially areas related to emotion, may also help. Improve symptoms of depression.

TDCS is one. Safe, effective treatmentwhich, in some studies, has been shown to assist patients. Get forgiveness And stay symptom-free for a month. However, previous clinical trials of tDCS required patients to go to a clinic or hospital to receive the treatment, despite the devices being quite portable.

But oh A recent randomized controlled trial It has now been shown that tDCS – delivered by the patient in their very own home with online virtual support – can result in a major reduction in depression.

To conduct their study, researchers recruited 174 patients with major depressive disorder within the United Kingdom and the United States. About 63 percent of those participants were classified as having treatment-resistant depression.

Half of the participants received tDCS treatment at home. This was delivered for half-hour a day, five times every week for 3 weeks to begin. Then, they dropped to a few sessions per week for seven weeks. As these sessions were conducted within the patient's own residence with distant support, this meant that there was no must visit a health care provider or nurse.

The other half of the patients were within the control group. These participants got a sham condition, where they wore an electrode strap but received no electrical stimulation.

After the initial ten-week study period, patients within the tDCS group were randomized to proceed treatment thrice per week. Those within the shame condition were also offered the energetic protocol.

Treatment at home was generally well tolerated. There were only just a few reports of adversarial reactions (primarily related to irritation across the stimulation site).

Patients in each groups a Depression Assessment Scale At the start and end of the study. This assessment asks patients a series of questions, then gives them a rating.

Any rating above ten indicates depression. Both the energetic tDCS and sham groups improved—nevertheless, the energetic tDCS group's scores decreased significantly more, reducing depression scores by greater than two points in comparison with the control group. is

Neuromodulation therapies

This study found that home-based tDCS shows great promise as an economical, convenient, and secure technique of providing treatment to patients with treatment-resistant depression.

This gives it a bonus over other types of neuromodulation therapy – resembling transcranial magnetic stimulation (TMS). TMS modulates brain activity by delivering magnetic pulses through an electromagnetic coil placed within the scalp.

Unlike TMS, which requires a visit to the clinic, tDCS is effective for home delivery.
Connect Images – Curated/Shutterstock

TMS has been shown to be effective. 50% of the time For patients with treatment-resistant depression when paired with psychotherapy. But one downside of TMS therapy is that it could actually only be delivered in a clinic or hospital to patients who need 30-minute treatments at the very least five times every week for six weeks for TMS to take effect.

Transcranial direct current stimulation therapy can also be distinguished Fewer side effects Compared to electroconvulsive therapy (ECT) which also passes electrical current through the brain. ECT can also be more invasive than tDCS since it requires anesthesia to be performed. In contrast, tDCS passes a weak electrical current through two contact points within the brain.

However, the authors make a crucial point regarding the treatment-resistant status of some participants.

Patients who had a history of depression and were refractory to a few or more treatments were excluded from the study. This signifies that future studies will need to research the efficacy threshold on the subject of tDCS at home – and whether it could actually also work for patients with more severe treatment-resistant depression.

Another factor that might be vital for future studies to research is whether or not the patient's home environment and social support network influence treatment efficacy. The next steps for researchers might be to grasp why depression occurs, the way it manifests itself, in addition to differences in acceptance and the way it's handled.

It may also be vital for future studies to account for physiological differences related to age, sex, race, socioeconomic status, and lots of other aspects which will influence the event of depression.

Still, this study shows that home delivery of tDCS results in significant improvements in mood in individuals with depression who've failed to reply to other treatments.